The Motley Fool

A FTSE 100 dividend growth stock I’d buy and hold all the way through to 2030

Image source: Getty Images.

As a holder of several FTSE 100 stocks myself, I have to admit that I’m far from concerned by the share market sell-off that has continued into another week.

Share market investment has been proven time and again to be one of the most effective ways of putting your money to work over the long-term. And I have no intention of selling any of my blue-chip holdings for at least another decade.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

A Footsie company that I haven’t bought into just yet is NMC Health (LSE: NMC). But given the strong probability that it should continue to thrive through the 2020s and beyond, I am seriously tempted to splash the cash on this healthcare star.

Forecasts bumped higher

Last time I covered NMC I mentioned the exceptional revenues possibilities created by its buzzing expansion drive across the United Arab Emirates, a strategy which is supplemented by clever acquisition action. And just this week the fruits of its programme were once again laid bare.

The firm said that it was revising up its forecasts for 2018 following a strong second half, and it now anticipates that revenues will rise 24% year-on-year, up 20 basis points from its prior projections. Consequently the hospital operator hiked its EBITDA guidance too, to $480m from $465m previously.

And this strong performance is expected to continue into next year, NMC predicting revenues rises of between 22% and 24% and EBITDA improvement in the range of 18% to 20%. The firm said that “2019 guidance will also point towards continuation of strong organic growth on the back of sustained ramp-up at key facilities, integration and expansion of acquired entities as well as strong operational performance.”

With the company pledging to continue opening new greenfield facilities and expanding its existing infrastructure next year too, there’s little reason to expect profits growth in the lucrative markets of the Middle East from continuing to charge beyond the medium term.  

In the meantime, NMC still has its pedal to the metal and this week announced it had signed off on a $1.6bn joint venture with Saudi Arabia’s state-run Hassana Investment Company to create a network of medical facilities in the kingdom with up to 3,000 beds.

Dividends detonating

NMC has been minded to supercharge the annual dividend in recent years as earnings have swelled by double-digit percentages. So no-one should be surprised that, with City analysts expecting profits to rise an extra 35% this year and 31% in 2019, payouts are anticipated to keep detonating.

Last year’s 13p per share reward is projected to rise to 19.4p in 2018 and again to 25.7p in 2019. These figures yield 0.6% and 0.8% respectively, figures which are admittedly not that impressive. But the pace at which the business could continue to raise dividends over the next decade as its investments pay off should encourage income seekers to take a look.

The current share price weakness at the business leaves it dealing on a sub-1 PEG reading of 0.8. This, in my opinion, reinforces its appeal as one of the most appetising FTSE 100 dividend growth stocks out there.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended NMC Health. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.